← Back to Clinical Trials
Recruiting NCT05578742

NCT05578742 V/Q Matching Variations With PEEP in ARDS According to Compliance-based Phenotypes (France)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05578742
Status Recruiting
Phase
Sponsor University Hospital, Angers
Condition ARDS
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-02-08
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
PEEP increasePEEP decrease

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2024-02-08 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aim to compare the effect of Positive End Expiratory Pressure (PEEP) on ventilation/perfusion mismatch in two phenotypes of patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS), characterized by their respiratory system elastance (Ers). Ventilation/perfusion mismatch will be assessed by Electrical Impedance Tomography (EIT).

Eligibility Criteria

Inclusion criteria: * intubated patients with moderate and severe ARDS (Berlin definition, PaO2/FiO2 ≤200 mmHg at PEEP 5 cmH2O) * undergoing deep sedation * on controlled mechanical ventilation * between 24 hours and 5 days after intubation. Exclusion criteria: * age \<18 years old; pregnancy * patient undergoing legal protection * contra-indications to EIT (e. g. severe chest trauma or wounds) * pneumothorax; patient undergoing ECMO * patient with BMI ≥35 kg/m2 * hemodynamic instability with MAP \<60 mmHg despite vasopressors.

Contact & Investigator

Central Contact

François Beloncle, MD

✉ francois.Francois.Beloncle@chu-angers.fr

📞 +33 241 35 58 65

Frequently Asked Questions

Who can join the NCT05578742 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying ARDS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05578742 currently recruiting?

Yes, NCT05578742 is actively recruiting participants. Contact the research team at francois.Francois.Beloncle@chu-angers.fr for enrollment information.

Where is the NCT05578742 trial being conducted?

This trial is being conducted at Angers, France.

Who is sponsoring the NCT05578742 clinical trial?

NCT05578742 is sponsored by University Hospital, Angers. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology